Resch, Irene
Shariat, Shahrokh F.
Gust, Kilian M.
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 19 January 2018
Accepted: 21 February 2018
First Online: 8 March 2018
Conflict of interest
: I. Resch declares that she has no competing interests. S.F. Shariat is a member of the advisory boards of and/or speaker for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Jansen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi and Wolff. He holds the following patents: “Method to determine prognosis after therapy for prostate cancer” (granted 6 September 2002), “Methods to determine prognosis after therapy for bladder cancer” (granted 19 June 2003), “Prognostic methods for patients with prostatic disease” (granted 5 August 2004) and “Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma” (granted 20 July 2010). K.M. Gust is a member of the advisory boards of Roche and Cepheid. He has been a speaker for Astellas, Astra Zeneca and Bristol-Myers Squibb, Ipsen, MSD and Roche and has received support for meeting and travel expenses by Allergan, Astellas, Astra Zeneca, Bayer Healthcare, Bristol-Myers Squibb, Janssen, Novartis, Pfizer, Pierre Fabre and Roche.